27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Alzheimer disease (AD) is the leading cause of dementia, with an estimated 6.9 million Americans aged 65 and older living with Alzheimer dementia today, with this number projected to grow to 13.8 million by 2060. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The advent of anti-amyloid therapies (AATs) for Alzheimer disease (AD) has elevated the importance of MRI surveillance for amyloid-related imaging abnormalities (ARIA) such as microhemorrhages and siderosis (ARIA-H) and edema (ARIA-E). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a growing global health concern that significantly impacts the quality of life for millions of individuals and imposes substantial burdens on healthcare systems. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Significant amygdala atrophy was observed in multiple amygdala nuclei across cognitive performance groups, with more pronounced changes in the low-performance group. 4 key findings →
Design: cross-sectional Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The subdivisions exhibit different pathways, terminations, and structural characteristics. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate estimation of Alzheimer's disease (AD) severity from structural magnetic resonance imaging (MRI) remains difficult, as disease-associated anatomical alterations are often subtle and publicly available datasets are typically too small to support robust deep learning model training. 1 key finding →
Participants: 214 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The capability of xEEGNet to filter specific EEG bands, learns band specific topographies and use the right EEG spectral bands for disease classification demonstrates its interpretability. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
AD patients exhibited a significant reduction in the water exchange rates across the BBB, whereas DLB patients showed a significant increase in BBB permeability to contrast agent. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Tau aggregates accumulate in the Alzheimer's disease (AD) brain according to the established Braak staging scheme and spread from transentorhinal over limbic regions to the neocortex. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Positron emission tomography (PET) imaging of brain amyloid beta is now clinically available in several countries including the United States and the United Kingdom, but not Canada. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We question the validity of the evidence for the removal of amyloid in particular as assessed by amyloid PET imaging, believing that what is observed is more likely a large nonspecific amyloid PET signal in the white matter that diminishes during immunotherapy-in line with dose-dependent increases in amyloid-related imaging abnormalities and increased loss of cerebral volume in treated compared with placebo patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Magnetic resonance imaging (MRI) can measure transverse relaxation rate (R2) of tissues. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Numerous studies have shown a marked decrease of beta-amyloid(42) (Abeta(42)) in the cerebrospinal fluid (CSF) of patients with incipient Alzheimer's disease (AD). 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
FLIO set-up uses a scanning laser ophthalmoscope (HRA2, Heidelberg Engineering, Germany), which was modified by the use of an excitation pulse laser BLD440 (Becker&Hickl, Berlin, Germany) and detection of fluorescence lifetime by time-correlated single photon counting (TCSPC; Becker&Hickl) in two spectral channels (channel 1: 490-560 nm, channel 2: 560-700 nm). 4 key findings →
Participants: 16 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Selecting a set of relevant markers to predict conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has become a challenging task given the wealth of regional pathologic information that can be extracted from multimodal imaging data. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Olfactory impairment is associated with prodromal Alzheimer's disease (AD) and is a risk factor for the development of dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Amyloid-targeted monoclonal antibody therapies have introduced a new era in the treatment of early Alzheimer disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MobileNet achieved the highest overall performance, with an accuracy of 99.44%. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The model achieves accuracy rates of 94% on the brain tumor dataset, 81% on the augmented Alzheimer dataset, and 93% on the third dataset, underscoring its capability to differentiate various neurological conditions. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 51 patients with AD, age (median: 73 years) and 53 cognitively normal subjects (median age: 69) were included. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
IRMA can be used to learn and disregard center-specific information in features extracted from brain $$^{18}$$ 18 F-FDG PET scans, while retaining disease-specific information. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Accurate identification of neurodegenerative disorders, including Alzheimer’s Disease (AD) and Frontotemporal Dementia (FTD), is crucial for prompt medical intervention. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
DNA methylation is a critical epigenetic mechanism involved in numerous physiological processes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There are meaningful differences in the readability of patient information generated by different large language models. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Perspectivas futuras O mesmo princípio de modulação glial pode ser aplicado em cenários de morte clínica (parada cardiorrespiratória). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 1,159 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →